Trial Search Results
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Abbott Medical Devices
- Device: MitraClip™ device implantation
- Procedure: Mitral Valve Repair Surgery
- Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
- The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
- Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery pressure systolic pressure > 50 mmHg, or LVESD > 40 mm.
- Subject is at moderate surgical risk defined as being at least 75 years of age, OR if
younger than 75 years, then has: (1) Society of Thoracic Surgeons (STS) Predicted Risk
of Mortality (PROM) Repair Score ≥ 2%, OR (2) Presence of other comorbidities which
may introduce a potential surgery-specific impediment.
- Subject provides written informed consent.
- Subject is ≥ 18 years of age.
- Subject is currently participating in another clinical investigation
- Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
- Subject has ischemic or non-ischemic secondary MR
- Concomitant severe tricuspid valve regurgitation
- Ejection fraction <30%
- Severe mitral annular calcification
- Acute myocardial infarction in the past 12 weeks
- Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
- Subjects who have concurrent coronary artery disease may be included provided the
subjects are eligible for both percutaneous coronary intervention (PCI) and coronary
artery bypass surgery. Subjects randomized to the device group, must undergo PCI
before the MitraClipTM device procedure. Subjects randomized to the surgical (control)
arm may undergo coronary artery revascularization during mitral valve repair surgery
- Surgical procedure performed in the past 30 days
- Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
- Transesophageal echocardiography (TEE) is contraindicated.
- Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock or the need for inotropic support or IABP
- Need for emergency surgery for any reason
- Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
- Systolic anterior motion of the mitral valve
- Hypertrophic cardiomyopathy
- Renal insufficiency requiring dialysis
- Active infections requiring current antibiotic therapy
- Subjects who are pregnant or planning to be pregnant
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study